Shattuck Labs, Inc.

STTK

US82024L1035

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-28 pm EDT			5-day change	1st Jan Change
3.86 ^USD	+2.93%		-11.67%	-45.86%

Jun. 20	HC Wainwright Adjusts Price Target on Shattuck Labs to $16 From $28, Maintains Buy Rating	MT
Jun. 17	Citigroup Adjusts Shattuck Labs Price Target to $9 From $10, Maintains Buy Rating	MT

Shattuck Labs, Inc. announced that it has received $19.999998 million in funding from Redmile Group, LLC

December 25, 2023

On December 26, 2023, Shattuck Labs, Inc closed the transaction.

Latest news about Shattuck Labs, Inc.

HC Wainwright Adjusts Price Target on Shattuck Labs to $16 From $28, Maintains Buy Rating	Jun. 20	MT
Citigroup Adjusts Shattuck Labs Price Target to $9 From $10, Maintains Buy Rating	Jun. 17	MT
BTIG Downgrades Shattuck Labs to Neutral From Buy	Jun. 17	MT
Needham Adjusts Shattuck Labs Price Target to $8 From $12, Maintains Buy Rating	Jun. 14	MT
Transcript : Shattuck Labs, Inc. - Special Call	Jun. 14
Shattuck Labs, Inc. Announces Committee Appointments	Jun. 11	CI
Shattuck Labs Says FDA Grants Orphan Drug Designation to Leukemia Drug; Shares Rise	Jun. 10	MT
Shattuck Labs Gets FDA's Orphan Drug Status for Leukemia Treatment	Jun. 10	DJ
Shattuck Labs, Inc. Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration for SL-172154 for the Treatment of Acute Myeloid Leukemia	Jun. 10	CI
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of Sl-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (Hr-Mds) and Tp53 Mutant Acute Myeloid Leukemia Patients At the European Hematology Association 2024 Congress	May. 14	CI
Shattuck Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Shattuck Labs, Inc. Announces Board Appointments	Mar. 04	CI
Sector Update: Health Care Stocks Rising Late Afternoon	Mar. 01	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	Mar. 01	MT
Shattuck Labs Shares Rise as Q4 Net Loss Narrows	Mar. 01	MT
Shattuck Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Shattuck Labs, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Shattuck Labs Collaborates With Ono Pharmaceutical to Develop Fusion Proteins	Feb. 14	MT
Shattuck Strikes Joint Development Deal With Japan's Ono Pharma	Feb. 13	DJ
Shattuck Labs, Inc. Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases	Feb. 13	CI
Shattuck Labs Insider Sold Shares Worth $250,000, According to a Recent SEC Filing	Jan. 16	MT
Transcript : Shattuck Labs, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 12:00 PM	Jan. 11
Shattuck Labs, Inc. announced that it has received $19.999998 million in funding from Redmile Group, LLC	Dec. 25	CI
Shattuck Labs, Inc. Files Initial Topline Dose-Exp Expansion Data from Its Ongoing Phase 1A/B Clinical Trial of Sl-172154 in Frontline Tp53m Aml and Tp53m Aml Patients	Dec. 21	CI
Shattuck Labs, Inc. announced that it expects to receive $19.999998 million in funding	Dec. 20	CI

Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Shattuck Labs, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.86 USD

Average target price

9.5 USD

Spread / Average Target

+146.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SHATTUCK LABS, INC.	-45.86%	184M
MODERNA, INC.	+19.41%	45.51B
LONZA GROUP AG	+38.65%	39.36B
IQVIA HOLDINGS INC.	-8.62%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
CELLTRION, INC.	-13.50%	26.03B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B

Other Biotechnology & Medical Research